Differential Sensitivity of ERBB2 Kinase Domain Mutations towards Lapatinib

BACKGROUND: Overexpression of the ERBB2 kinase is observed in about one-third of breast cancer patients and the dual ERBB1/ERBB2 kinase inhibitor lapatinib was recently approved for the treatment of advanced ERBB2-positive breast cancer. Mutations in the ERBB2 receptor have recently been reported in...

Descripción completa

Detalles Bibliográficos
Autores principales: Kancha, Rama Krishna, von Bubnoff, Nikolas, Bartosch, Natalie, Peschel, Christian, Engh, Richard A., Duyster, Justus
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2011
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3203921/
https://www.ncbi.nlm.nih.gov/pubmed/22046346
http://dx.doi.org/10.1371/journal.pone.0026760

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3203921/
https://www.ncbi.nlm.nih.gov/pubmed/22046346
http://dx.doi.org/10.1371/journal.pone.0026760

Ejemplares similares